AIDS Presentation

AIDS Presentation - The HIV/AIDS part of the presentation...

Info iconThis preview shows pages 1–3. Sign up to view the full content.

View Full Document Right Arrow Icon
The HIV/AIDS part of the presentation will examine the effects of HIV/AIDS in Africa, in terms of the impact on present and future generations. We will look at the efforts that have been made over the course of the past ten years, the successes and failures, and the way forward. FACT: If we could cure AIDS with a glass of clean water, we would not be able to cure half of the AIDS victims in the world. HIV is an uncommon type of virus called a retrovirus, and drugs developed to disrupt the action of HIV are known as anti- retrovirals or ARVs. These come in a variety of formulations designed to act on different stages of the life-cycle of HIV. The AIDS virus mutates rapidly, which makes it extremely skilful at developing resistance to drugs. To minimize this risk, people with HIV are generally treated with a combination of ARVs that attack the virus on several fronts at once. If treatment is discontinued the virus becomes active again, so a person on ARVs must take them for life. Access to drugs depends not only on financial and human resources. It depends also on people who need them being aware of their HIV status, knowledgeable about treatment, and empowered to seek it. Thus public information and education are important elements in widening access, alongside efforts to build or strengthen the health services. Intellectual property refers to creations of the mind—inventions, literary and artistic works, symbols, names, images, and designs used in commerce. Intellectual property is divided into two categories: industrial property (which includes inventions and is covered by patents) and copyright (which covers literary and artistic works).
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
HIV-related intellectual property falls into the first category and includes a number of important AIDS medicines and diagnostics. The patents on these products grant the pharmaceutical companies that developed them exclusive rights to make and market them for a certain period of time, typically 20 years. The purpose of the patent is to act as an incentive for companies to make considerable investment in research and development of new drugs, knowing that, with a monopoly in the market place, they stand a good chance of recouping their investment and making a profit. Prices have been set that are far beyond the reach of developing countries. IMPACT Like a pebble dropped in a pool, HIV sends ripples to the edges of society, affecting first the family, then the community, then the nation as a whole. During 2006 alone, an estimated 2.1 million adults and children died as a result of AIDS in Sub-Saharan Africa. Since the beginning of the epidemic more than 15 million Africans have died from AIDS In all affected countries the AIDS epidemic is bringing additional pressure to bear on the health sector. As the epidemic matures, the demand for care for those living with HIV rises, as does the toll of AIDS on health workers. In sub-Saharan Africa, the direct medical costs of AIDS (excluding
Background image of page 2
Image of page 3
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 04/19/2008 for the course ECON 200 taught by Professor Souza during the Spring '08 term at McGill.

Page1 / 10

AIDS Presentation - The HIV/AIDS part of the presentation...

This preview shows document pages 1 - 3. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online